Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa

Biohaven Ltd. (NYSE:BHVN) is one of the 10 Small–Cap Stocks Insiders Are Buying Recently.

On March 19, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in a Phase 2 proof-of-concept study of taldefgrobep alfa, a myostatin-activin pathway inhibitor aimed at achieving weight loss in people with obesity. The company expects topline data in the second half of 2026.

On March 11, 2026, TD Cowen analyst Ken Cacciatore raised the price target on Biohaven Ltd. (NYSE:BHVN) to $30 from $15 and maintained a Buy rating. Ken Cacciatore updated the model following validation of the Kv7 mechanism of action in focal epilepsy based on azetukalner data and said this supports expectations ahead of topline opakalim data expected mid-year, while noting potential to highlight a differentiated CNS adverse event profile.

Earlier in March, Biohaven Ltd. (NYSE:BHVN) reported Q4 adjusted EPS of (90c), compared to the (96c) consensus estimate. CEO Vlad Coric said the company made “significant progress” advancing its pipeline, highlighting its degrader platform as a “central pillar” of strategy and pointing to early evidence demonstrating the ability to target disease mechanisms while preserving immune function, supporting confidence in the platform’s potential.

Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa

Biohaven Ltd. (NYSE:BHVN) develops therapies across immunology, neuroscience, and oncology.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.